Single-Dose Fed Bioequivalence Study of Nisoldipine Extended-Release Tablets (40 mg; Mylan) and Sular® Extended-Release Tablets (40 mg; First Horizon) in Healthy Volunteers

NCT00979537 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

83

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Nisoldipine Extended-release Tablets, 40 mg
DRUG: Sular Tablets, 40 mg

Sponsor

Mylan Pharmaceuticals Inc